Apical sodium-dependent bile acid transporter inhibition in children with Alagille syndrome

Affiliations

¹ Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Division of Gastroenterology, Hepatology and Nutrition at Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA. Electronic address: akriegermeier@luriechildrens.org.
² Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Division of Gastroenterology, Hepatology and Nutrition at Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.

Comment

Alyssa Kriegermeier et al. Lancet. 2021.

. 2021 Oct 30;398(10311):1544-1545.

doi: 10.1016/S0140-6736(21)01447-1. Epub 2021 Oct 28.

¹ Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Division of Gastroenterology, Hepatology and Nutrition at Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA. Electronic address: akriegermeier@luriechildrens.org.
² Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Division of Gastroenterology, Hepatology and Nutrition at Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.

No abstract available

Conflict of interest statement

We declare no competing interests.

Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
Gonzales E, Hardikar W, Stormon M, Baker A, Hierro L, Gliwicz D, Lacaille F, Lachaux A, Sturm E, Setchell KDR, Kennedy C, Dorenbaum A, Steinmetz J, Desai NK, Wardle AJ, Garner W, Vig P, Jaecklin T, Sokal EM, Jacquemin E. Gonzales E, et al. Lancet. 2021 Oct 30;398(10311):1581-1592. doi: 10.1016/S0140-6736(21)01256-3. Epub 2021 Oct 28. Lancet. 2021. PMID: 34755627 Clinical Trial.